The BABAM1 Knockout Jurkat Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the BABAM1 gene in the Jurkat T lymphocyte line. This polyclonal format provides a heterogeneous loss-of-function model suitable for pooled functional screens, bulk proteomic analyses, and population-based phenotypic studies without the limitations of clonal selection. This CRISPR/Cas9-edited model enables investigation of the collective effects of BABAM1 loss in cellular processes for mechanistic and translational studies.
Jurkat cells are an immortalized human T cell line derived from acute T cell leukemia, widely used to study TCR signaling, activation, and apoptosis. This background provides a relevant context for investigating BABAM1 functions in DNA damage signaling and type I interferon responses, which influence T cell survival, proliferation, and immune function.
BABAM1 (BRISC and BRCA1-A complex member 1) is an essential component of two distinct multiprotein complexes: the BRCA1-A complex and the BRISC deubiquitinase complex. In the BRCA1-A complex, BABAM1 partners with RAP80, ABRAXAS1, BRCC3, and BABAM2 to recognize polyubiquitin chains on histones at sites of DNA double-strand breaks. This recognition facilitates the recruitment of BRCA1 and promotes homologous recombination repair while antagonizing 53BP1-dependent non-homologous end joining. In the BRISC complex, BABAM1 associates with FAM175B (ABRO1) to deubiquitinate and stabilize the type I interferon receptor IFNAR1, sustaining cytokine signal transduction. Downstream of IFNAR1, JAK-STAT signaling activates STAT1, STAT2, and IRF9, inducing interferon-stimulated genes. Consequently, BABAM1 integrates DNA damage sensing and innate immune signaling, positioning it at a nexus between genome stability and inflammation.
In Jurkat T cells, BABAM1 knockout is anticipated to influence both the DNA damage response and interferon-mediated signaling pathways. Given the dual role of BABAM1, disruption may shift the balance of DNA repair toward mutagenic non-homologous end joining, potentially increasing genomic instability??a hallmark of T cell leukemogenesis. Simultaneously, impaired stabilization of IFNAR1 could attenuate type I interferon signaling, altering the expression of interferon-stimulated genes and modulating T cell activation or apoptosis. This dual perturbation makes the knockout model especially valuable for examining how genome maintenance mechanisms and inflammatory cues intersect in a T cell context, providing insights into T cell malignancies, autoimmune disorders, and cancer immunotherapy.
Researchers can employ these knockout cells in a variety of experimental frameworks. Western blotting and immunofluorescence can confirm BABAM1 disruption and measure DNA damage markers such as ??H2AX, RAD51, and 53BP1 foci. Flow cytometry enables quantification of surface IFNAR1 levels, while RT-qPCR assesses expression of interferon-stimulated genes. Functional assays include comet assay for DNA damage, T cell activation monitoring via CD69 upregulation, drug sensitivity profiling with PARP inhibitors or genotoxic agents, and cell viability assessments. The polyclonal population is suitable for CRISPR screening libraries or chemical screens targeting the BRCA1-A and BRISC complexes. For technical support, contact Ascent Research.
